This report provides exclusive insights into the COVID-19 impact on the Antiviral Drugs Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Antiviral Drugs Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Antiviral Drugs Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on
antiviral drugs market provides in-depth analysis of segments and sub-segments
in global as well as regional antiviral drugs market. The study also highlights
the impact of drivers, restraints and macro indicators on the global and
regional antiviral drugs market over the short term as well as long term. The
report on global antiviral drugs market provides qualitative and quantitative
analysis for the period of 2016 to 2024. According to the report, the global
antiviral drugs market value is projected to grow with a CAGR of 4.1% from 2018
to 2024. The global antiviral drugs market size was totaled 43.01 Billion in
Global antiviral drugs market has grown moderately over the past few
years, but during the forecast period this market likely to have healthy gains.
As of 2017, as per the WHO, 36.7 Million people were living with HIV globally,
hence increased in viral infection incidences considered as one of the strong
driving force in this market. Due to which robust R&D activities, advanced
treatments and formulations such as vaccines, combination therapy, and others
introduced in the market. Moreover, Strong research and development activities have
led to the introduction of new drugs with better efficacy and fewer side effects
thereby contributing significantly in the global growth. On the other hand,
High risk of failure, higher cost associated with research and development
activities, and stringent government regulations are the major growth barriers
inhibiting global growth of this market.
Increasing incidences of epidemics in viral infections such as
influenza, respiratory syncytial virus, and others anticipated providing
massive growth opportunities for this market over the forecast period. Whereas,
High cost associated with the development of new drugs and the usage of natural
products will pose a major challenge in front of this market.
The report segments the global antiviral drugs market by drug type, by therapeutics,
by the end user, and by region. The market size of each segment has been provided
in terms of value (USD) and volume (tons). Market segmentation based on type
includes branded drugs and generic drugs. ON the basis of therapeutics global
market has been divided into HIV/Aids therapeutics, hepatitis (B&C)
therapeutics, herpes therapeutics, influenza therapeutics, and others
(Pneumonia). Market segmentation based on end user includes hospitals, clinics,
and ambulatory surgical center.
Geographic Coverage and Analysis:
The report provides regional analysis covering geographies such as North
America, Europe, Asia-Pacific, and Rest of the World. In this section, the key
trends and market size for each geography are provided over the period of 2015 - 2024. With over 30% of global market shares in the market,
North America was the largest consumer of antiviral drugs by the end of 2017.
In which the US drives the North America antiviral drugs market. Moreover, the US has a large number of HIV infected population, due to which there is vast demand for
antiviral drugs in this region, and has made this region largest consumer.
Factors including a high level of drug development, sophisticated healthcare
infrastructure, increasing awareness level, presence of key players in this the region have significantly contributed to the regional growth of North America.
Following North America, Europe is the second largest market. Germany, UK,
France and Italy are important markets in this region. The Asia-Pacific,
however, is anticipated to provide high potential growth throughout the
forecast period. The region will emerge with the highest CAGR on account of the presence of established generic industry, growing base of the target population,
and improving economic stability. Furthermore, India drives the APAC antiviral
therapeutics market by having the highest cases of HIV.
The companies covered in the report include Roche
Holding AG, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Healthcare,
Med Immune/AstraZeneca, Schering-Plough,
Johnson & Johnson, Merck & Co, Gilead Sciences, Dr. Reddy, and Cipla, Schering-Plough.
The report provides deep insights on demand forecasts, market trends, and
micro and macro indicators. In addition, this report provides insights into the
factors that are driving and restraining the demand for antiviral drugs globally
as well as regionally. Moreover, IGR-growth matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of antiviral
drugs. Moreover, the study highlights current market trends and provides forecast
from 2018 to 2024. We also have highlighted future trends in the antiviral
drugs market that will impact the demand during the forecast period. Moreover,
the competitive analysis given in each regional market brings an insight into the
market share of the leading players. Additionally, the analysis highlights the rise
and fall in the market shares of the key players in the market. This report
will help manufacturers, suppliers, and distributors of the antiviral drugs
market to understand the present and future trends in this market and formulate
their strategies accordingly.